Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$507.0K+83.03%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jay S. Duker
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 214
- Beta
- 1.64
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -8.75
Financials
Revenue
$507.0K+83.0%Net Income
$-94.47MEBITDA
$-93.14MFree Cash Flow
$-63.55MEPS (diluted)
$-1.09Shares Outstanding (diluted)
86.54M+2432.3%Operating Expenses
$97.89MCash & Debt
$180.47MReturn of Capital
$3.42MRevenue by Segment (annual)
$46.37MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $31.37M | $-231.96M | $-3.17 |
| 2024 | $43.27M | $-130.87M | $-2.32 |
| 2023 | $46.02M | $-70.80M | $-1.82 |
| 2022 | $41.40M | $-102.25M | $-2.74 |
| 2021 | $36.94M | $-58.42M | $-2.03 |
| 2020 | $34.44M | $-45.39M | $-3.54 |
| 2019 | $20.36M | $-56.79M | $-5.44 |
| 2018 | $5.86M | $-53.17M | $-12.71 |
| 2017 | $2.96M | $-53.17M | $-11.50 |
| 2016 | $7.54M | $-18.48M | $-5.23 |
| 2015 | $1.62M | $-21.55M | $-6.81 |
| 2014 | $26.57M | $6.35M | $2.20 |
| 2013 | $3.47M | $-13.36M | $-5.16 |
| 2012 | $2.14M | $-11.90M | $-5.20 |
Valuation
EYPThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+0.00%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·20d ago·Positive
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
View source ↗ - Newsseekingalpha.com·20d ago·Positive
EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:
View source ↗ - Newsbusinesswire.com·38d ago·Negative
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $EYPT--EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsseekingalpha.com·47d ago·Negative
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort. EYPT's management argues the failure was driven by nine patients (4%) with vision loss unrelated to wet AMD, and highlights strong secondary endpoints and durability advantages. Upcoming LUCIA Phase 3 data in Q4 2026 is pivotal; a positive result could revive the …
View source ↗ - Newsbenzinga.com·48d ago·Neutral
These Analysts Slash Their Forecasts On EyePoint EyePoint Inc. (NASDAQ:EYPT) on Monday released topline results from its pivotal Phase 3 LUGANO clinical trial evaluating DURAVYU for the treatment of wet age-related macular degeneration.
View source ↗ - Newszacks.com·48d ago·Negative
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
View source ↗ - Newsseekingalpha.com·48d ago·Positive
EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript
View source ↗ - Newsreuters.com·50d ago·Negative
EyePoint's eye drug misses main goal in late-stage trial EyePoint said on Monday its experimental eye drug failed to meet its main goal in a late-stage trial.
View source ↗ - Newsglobenewswire.com·52d ago·Positive
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.91 per share
Typical surprise -10.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.09 vs $-1.01miss
- Wed, May 6$-0.99 vs $-0.79miss
- Wed, Mar 4$-0.81 vs $-0.78miss
- Wed, Nov 5$-0.85 vs $-0.77miss
- Wed, Aug 6$-0.85 vs $-0.67miss
- Wed, May 7$-0.65 vs $-0.65beat
Estimates and results for EYPT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EYPT officers and directors.
- Bought
- $72k
- Sold
- $2.0m
2 trades
11 trades
- Zaderej Karen L.bought
- Ribeiro Ramirosold
- Ribeiro Ramirosold
- Ribeiro Ramirosold
- Duker Jay S.bought
- Ribeiro Ramirosold
- Ribeiro Ramirosold
- Ribeiro Ramirosold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EYPT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.